Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECT 2: Digital System vs Standard of Care in Asthma
NCT04677959Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluticasone propionate nasal spray and salmeterol in asthma (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control at 24 weeks. Started Feb 2021; status: completed.
02
Drugs
fluticasone propionate nasal spraysalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04677959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677959.